Drop In Clinical Trials In India Is A Cause Of Concern For Healthcare Research

By Author: Mrss India
Total Articles: 2
Comment this article

From quite a long time, India is one of the preferred destinations for healthcare research outside the USA. Not only clinical trials but market segmentation research and testing effectiveness of new drugs were the major areas of interest for drug companies. Healthcare Market Research India brought a phenomenal boost to the economy. However, recent trends show that there is a decline in Pharma Research India. Companies prefer other countries of the third world, or they prefer China for extensive drug research. It is a cause of concern because the drop in the healthcare research means there is less investment in the sector by big multinationals.

Decline in health care research has a multidimensional impact

Market Research Agencies India suspect a big impact due to a decline in healthcare research in the country. They feel that since companies are not investing for extensive clinical trials, they will not share the formula with the Indian companies or even subsidiaries owned by them. Hence, there will be no further production of new drugs in India. Importers and consumers will be forced to pay a higher price for the ...
... same. It will make the medicines out of reach for the common people. Therefore, the government has to take measures for
regularizing the same.

How is market research being controlled in India?

Predominantly, it is being controlled by DCGI (Drug Control General India). It is a government agency that gives approval for clinical trials. It is also responsible for enforcing norms of marketing and manufacturing medicines in India. It makes sure that the research is being conducted by following the international standards. Market Research Companies Asia rate DGCI quite superior in terms of maintaining high standards of Pharma research India. With stringent controls, well-developed training modules, and high emphasis on quality, it makes sure that each product is world-class.

Advertising Research India perceives India a robust country from the regulatory perspective; it is equally true that the majority of people in the country are illiterate and poor. They can’t afford big spending on medicines and rely on low-quality local drugs. Hence, they are vulnerable to side-effects and unethical trials. It is important that pharmaceutical companies take measures to make people aware of the importance of good quality medicines. Since branded drugs pass through the process of clinical trials, there is the minimal possibility of mishaps. Structured and coordinated efforts by pharmaceutical companies, research institutes, and regulatory authorities will boost the clinical trials in India.